Views: 1,445 | Downloads:
23
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Comparison of Oral versus Intravenous Ramosetron in Prevention of Acute t Cisplatin-Induced Emesis: A Randomized Controlled Trial
Tantipalakorn C 
,
Srisomboon J ,
Thienthong H ,
Pantusart A ,
Suprasert P ,
Saereesongkhun C ,
Eamtang S ,
Sutthichat A ,
Pautad N
,
Srisomboon J ,
Thienthong H ,
Pantusart A ,
Suprasert P ,
Saereesongkhun C ,
Eamtang S ,
Sutthichat A ,
Pautad N JATUPOL SRISOMBOON, MD*,
AREE PANTUSART, BSc*,
CHANRAM SAEREESONGKHUN, BSc**,
AMPHIKA SUTTHICHAT, BSc**,
Objective : To compare the antiemetic efficacy of a single oral
versus
intravenous (IV)
ramosetron, a new class of selective 5-HT
3
receptor antagonists, in gynecologic cancer patients receiving
high-dose cisplatin.
Method : Between February 2003 and July 2003, 109 patients with gynecologic cancer sche-
duled to receive single agent cisplatin chemotherapy at a dose of 75 mg/m
2
were randomized to receive
either 0.2 mg oral (51 cases) or 0.3 mg IV (58 cases) ramosetron 1 hand 30 min respectively before
chemotherapy. Patients were evaluated for 24 h after chemotherapy. The number of nausea and vomit-
ing including adverse events were recorded every 6 h.
Results: 51 and 58 patients received oral and IV ramosetron respectively. Both groups were
similar regarding age, performance status, body mass index and diagnosis of gynecologic cancer. 95
per cent of cases were cervical cancer. Antiemetic effect was significantly higher in the oral group
when compared with the IV group during the first 6 hours and during the period of 18 to 24 hours
after administration of cisplatin chemotherapy. Overall in 24 h, patients receiving oral ramosetron
experienced no emesis slightly higher than that of the IV group (55% and 36% respectively, p
=
0.05).
Adverse events were mild and transient and were not significantly different in both groups, except
tiredness which was more frequent in the IV group.
Conclusion : Oral ramosetron at a dosage of 0.2 mg is as effective as 0.3 mg of intravenous
ramosetron in prevention of acute emesis in patients receiving 75 mg/m
2
of cisplatin chemotherapy.
Key word : Ramosetron, Cisplatin, Chemotherapy, Antiemesis
AREE PANTUSART, BSc*,
CHANRAM SAEREESONGKHUN, BSc**,
AMPHIKA SUTTHICHAT, BSc**,
Objective : To compare the antiemetic efficacy of a single oral
versus
intravenous (IV)
ramosetron, a new class of selective 5-HT
3
receptor antagonists, in gynecologic cancer patients receiving
high-dose cisplatin.
Method : Between February 2003 and July 2003, 109 patients with gynecologic cancer sche-
duled to receive single agent cisplatin chemotherapy at a dose of 75 mg/m
2
were randomized to receive
either 0.2 mg oral (51 cases) or 0.3 mg IV (58 cases) ramosetron 1 hand 30 min respectively before
chemotherapy. Patients were evaluated for 24 h after chemotherapy. The number of nausea and vomit-
ing including adverse events were recorded every 6 h.
Results: 51 and 58 patients received oral and IV ramosetron respectively. Both groups were
similar regarding age, performance status, body mass index and diagnosis of gynecologic cancer. 95
per cent of cases were cervical cancer. Antiemetic effect was significantly higher in the oral group
when compared with the IV group during the first 6 hours and during the period of 18 to 24 hours
after administration of cisplatin chemotherapy. Overall in 24 h, patients receiving oral ramosetron
experienced no emesis slightly higher than that of the IV group (55% and 36% respectively, p
=
0.05).
Adverse events were mild and transient and were not significantly different in both groups, except
tiredness which was more frequent in the IV group.
Conclusion : Oral ramosetron at a dosage of 0.2 mg is as effective as 0.3 mg of intravenous
ramosetron in prevention of acute emesis in patients receiving 75 mg/m
2
of cisplatin chemotherapy.
Key word : Ramosetron, Cisplatin, Chemotherapy, Antiemesis
Download:
PDF